0
Original Research: INFECTION |

Pulmonary Mycobacterium kansasii Infection in Israel, 1999–2004*: Clinical Features, Drug Susceptibility, and Outcome

David Shitrit, MD; Gerry L. Baum, MD; Rachel Priess, BA; Anita Lavy, MSc; Ariella Bar-Gil Shitrit, MD; Meir Raz, MD; Dekel Shlomi, MD; Bendayan Daniele, MD; Mordechai R. Kramer, MD, FCCP
Author and Funding Information

*From the Pulmonary Institute (Drs. D. Shitrit, Shlomi, Daniele, and Kramer), Rabin Medical Center, Beilinson Campus, Petah Tiqwa; Israel Lung Association (Dr. Baum), Tel Aviv; Macabbi Medical Service (Ms. Priess and Dr. Raz), Tuberculosis Center, Rehovot; Public Health Tel Aviv (Ms. Lavy), Israel Ministry of Health, Tel Aviv; and Department of Internal Medicine (Dr. A. B-G. Shitrit), Shaare-Zedek Medical Center, Jerusalem, Israel.

Correspondence to: Mordechai R. Kramer, MD, Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa 49100, Israel; e-mail: davids3@clalit.org.il



Chest. 2006;129(3):771-776. doi:10.1378/chest.129.3.771
Text Size: A A A
Published online

Background: Mycobacterium kansasii infection is one of the most common causes of nontuberculous mycobacterial lung disease in world. However, little is known about its background characteristics or drug sensitivity in nonendemic areas.

Design: We assessed the clinical features, radiologic findings, and drug sensitivity associated with M kansasii infection in Israel.

Methods: Patients with a culture-positive diagnosis of M kansasii infection between April 1999 and April 2004 were identified from a clinic database of tuberculosis centers. Mycobacterial cultures were performed with standard methods. Data on patient background and clinical features were collected from the medical files.

Results: Mean age (± SD) of the 56 patients was 58 ± 18 years, and 64% were men; 59% had associated lung disease. Fifteen percent were receiving immunosuppressive medications. None had HIV infection. Systemic comorbid diseases were noted in 27%. The most common clinical presentations were chest pain, cough, hemoptysis, fever, and night sweats. Cavitation was noted only in 54%. Older patients had more noncavitary disease than younger patients (p = 0.01, r = 0.35). Lower-lobe predominance was very rare (4%). None of the patients presented with pleural effusion or lymphadenopathy. Only seven patients (11%) underwent bronchoscopy for diagnosis. M kansasii isolates showed the highest sensitivity to rifampin, ethambutol, clarithromycin, and ofloxacin, and the highest resistance to ciprofloxacin and capreomycin. The mean duration of treatment was 21 ± 7.2 months. There were no disease-related deaths.

Conclusions: M kansasii disease in Israel has no association with HIV, more systemic comorbid diseases and associated lung disease, and fewer cavitations. Following appropriate treatment, patients with M kansasii disease have an excellent prognosis.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543